Inflammasome Therapeutics Says Study Published Today in Proceedings of the National Academy of Sciences Provides Human Data Confirming Potential of Company’s Proprietary Compounds for Prevention of Dry AMD
NEWTON, Mass.--(BUSINESS WIRE)-- #InflammasomeTherapeutics--Study published today provides human data confirming potential of Inflammasome Therapeutics' Kamuvudines for prevention of Dry AMD